Safety and Immunogenicity of ChimeriVax-WN02 West Nile Vaccine in Healthy Adults

Summary

The purpose of this study is to determine whether a single subcutaneous injection of ChimeriVax-WN02 vaccine is well tolerated, safe and induces protective antibodies against West Nile Disease. The study is divided into two parts; in the first part, a comparison of 3 dose levels of the vaccine will be made, with an inactive control. In the second part, the optimum dose level chosen after the first part will be given to older volunteers.

Timeline

Start

2005-12

Primary completion

2008-06

Completion

2009-04

Publications

• Biedenbender R, Bevilacqua J, Gregg AM, Watson M, Dayan G. Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults. J Infect Dis. 2011 Jan 1;203(1):75-84. doi: 10.1093/infdis/jiq003.

Drugs

Indications